Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Sopharma AD-Sofia's operating assets for the quarter that ended in Mar. 2026 was zł4,576 Mil. Sopharma AD-Sofia's operating liabilities for the quarter that ended in Mar. 2026 was zł1,019 Mil. Sopharma AD-Sofia's Total Assets for the quarter that ended in Dec. 2025 was zł4,672 Mil. Therefore, Sopharma AD-Sofia's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.76.
Sopharma AD-Sofia Scaled Net Operating Assets Related Terms
Sopharma AD-Sofia Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia Scaled Net Operating Assets Chart
WAR:SPH vs MCK, CAH, COR: Scaled Net Operating Assets Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Scaled Net Operating Assets vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.76 mean?
Sopharma AD-Sofia (WAR:SPH) has a Scaled Net Operating Assets of 0.76 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Scaled Net Operating Assets too high?
Sopharma AD-Sofia's current Scaled Net Operating Assets is 0.76. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Scaled Net Operating Assets compare to MCK and CAH?
Sopharma AD-Sofia's Scaled Net Operating Assets of 0.76 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Distribution company?
A good Scaled Net Operating Assets depends on the Medical Distribution industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Scaled Net Operating Assets is 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.52, compared to a current price of zł7.78 — trading 42.5% below its estimated fair value. The current Scaled Net Operating Assets is 0.76. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Scaled Net Operating Assets is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.78 is trading 42.5% below its estimated GF Value™ of zł13.52.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Scaled Net Operating Assets: 0.76
GF Value™: zł13.52 vs. price of zł7.78 (42.5% below fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
